BACKGROUND & AIMS: The biguanide drug metformin has recently been found to improve steatosis and liver damage in animal models and in humans with nonalcoholic steatohepatitis. METHODS: The aim of the present study was to determine whether metformin also prevents steatosis and liver damage in mouse models of acute and chronic alcohol exposure. RESULTS: Acute ethanol exposure caused a >20-fold increase in hepatic lipids, peaking 12 hours after administration. Metformin treatment significantly blunted the ethanol effect by >60%. Although metformin is a known inducer of AMP kinase (AMPK) activity, the hepatoprotective property of metformin did not correlate with activation of AMPK or of AMPK-dependent pathways. Instead, the protective effects of metformin correlated with complete prevention of the upregulation of plasminogen activator inhibitor (PAI)-1 caused by ethanol. Indeed, a similar protective effect against acute alcohol-induced lipid accumulation was observed in PAI-1-/- mice. Hepatic fat accumulation caused by chronic enteral ethanol feeding was also prevented by metformin or by knocking out PAI-1. Under these conditions, necroinflammatory changes caused by ethanol were also significantly attenuated. CONCLUSIONS: Taken together, these findings suggest a novel mechanism of action for metformin and identify a new role of PAI-1 in hepatic injury caused by ethanol.
BACKGROUND & AIMS: The biguanide drug metformin has recently been found to improve steatosis and liver damage in animal models and in humans with nonalcoholic steatohepatitis. METHODS: The aim of the present study was to determine whether metformin also prevents steatosis and liver damage in mouse models of acute and chronic alcohol exposure. RESULTS: Acute ethanol exposure caused a >20-fold increase in hepatic lipids, peaking 12 hours after administration. Metformin treatment significantly blunted the ethanol effect by >60%. Although metformin is a known inducer of AMP kinase (AMPK) activity, the hepatoprotective property of metformin did not correlate with activation of AMPK or of AMPK-dependent pathways. Instead, the protective effects of metformin correlated with complete prevention of the upregulation of plasminogen activator inhibitor (PAI)-1 caused by ethanol. Indeed, a similar protective effect against acute alcohol-induced lipid accumulation was observed in PAI-1-/- mice. Hepatic fat accumulation caused by chronic enteral ethanol feeding was also prevented by metformin or by knocking out PAI-1. Under these conditions, necroinflammatory changes caused by ethanol were also significantly attenuated. CONCLUSIONS: Taken together, these findings suggest a novel mechanism of action for metformin and identify a new role of PAI-1 in hepatic injury caused by ethanol.
Authors: Ina Bergheim; James P Luyendyk; Chad Steele; Gilandra K Russell; Luping Guo; Robert A Roth; Gavin E Arteel Journal: J Pharmacol Exp Ther Date: 2005-12-01 Impact factor: 4.030
Authors: R G Thurman; B U Bradford; Y Iimuro; K T Knecht; G E Arteel; M Yin; H D Connor; C Wall; J A Raleigh; M V Frankenberg; Y Adachi; D T Forman; D Brenner; M Kadiiska; R P Mason Journal: J Gastroenterol Hepatol Date: 1998-09 Impact factor: 4.029
Authors: Lauren G Poole; Veronica L Massey; Deanna L Siow; Edilson Torres-Gonzáles; Nikole L Warner; James P Luyendyk; Jeffrey D Ritzenthaler; Jesse Roman; Gavin E Arteel Journal: Am J Respir Cell Mol Biol Date: 2017-09 Impact factor: 6.914
Authors: Juliane I Beier; James P Luyendyk; Luping Guo; Claudia von Montfort; Donald E Staunton; Gavin E Arteel Journal: Hepatology Date: 2009-05 Impact factor: 17.425
Authors: Michael M Chen; Stewart R Carter; Brenda J Curtis; Eileen B O'Halloran; Richard L Gamelli; Elizabeth J Kovacs Journal: J Burn Care Res Date: 2017 Jan/Feb Impact factor: 1.845